Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis
J. Clin. Invest. Craig E. Daniels, et al. 114:1308 doi:10.1172/JCI19603 [Go to this article.]

Figure 4
c-Abl is required for TGF-β–induced morphologic alteration and cell proliferation. (A) AKR-2B cells, Abl^–/–Arg^–/– MEFs, or Abl^–/–Arg^–/– fibroblasts stably expressing (+) WT-c-Abl or dominant negative c-Abl (DN-c-Abl) were grown to confluence as described in Methods. Cultures were stimulated with DMEM alone or supplemented (+) with 5 μg/ml imatinib and/or 10 ng/ml TGF-β2. Following 48-hour incubation, representative areas were photographed at 20 phase. (B) Triplicate plates from A were trypsinized, and cells were counted with a hemocytometer.